News
LivaNova Reports Second-Quarter 2022 Results
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today reported results for the quarter ended June 30, 2022.
Financial Summary and Highlights1
-
Revenue
Humana Foundation Donates $500,000 to Support Recovery in Wake of Devastating Flooding
The Humana Foundation, the philanthropic arm of Humana Inc. (NYSE: HUM) for the past 40 years, is donating $500,000 towards relief and recovery efforts for those impacted by torrential rains and
Agilent Acquires Polymer Standards Service, Broadening Offerings for GPC/SEC Polymer Analysis
Agilent Technologies Inc. (NYSE: A) today announced it has acquired Polymer Standards Service GmbH (PSS), a provider of solutions in the field of polymer characterization. PSS specializes in
Agilent Announces Thought Leader Award to Gerhardt Attard at University College London (UCL)
Agilent Technologies Inc. (NYSE: A) today announced that Professor Gerhardt Attard has been selected to receive a prestigious Agilent Thought Leader Award. Prof Attard is a John Black Charitable
Dexcom ONE real-time Continuous Glucose Monitoring (rt-CGM) System available on prescription in the UK, improving access to rt-CGM for people with diabetes
DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, and NHS England today announced the availability of the easy to use Dexcom ONE
Dexcom ONE real-time Continuous Glucose Monitoring (rt-CGM) System available on prescription in the UK, improving access to rt-CGM for people with diabetes
DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, and NHS England today announced the availability of the easy to use Dexcom ONE
Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the course of autoimmune disease, announced that
Humana ranked No. 1 among health insurers for Customer Experience
For two years in a row, Humana ranked No. 1 among health insurers for customer experience (CX) quality in Forrester’s proprietary 2022 U.S. Customer Experience Benchmark survey. The ranking was
Dexcom Reports Second Quarter 2022 Financial Results
DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended June 30, 2022.
Second Quarter 2022 Financial Highlights:
-
Revenue grew 17% versus the same
Dexcom Reports Second Quarter 2022 Financial Results
DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended June 30, 2022.
Second Quarter 2022 Financial Highlights:
-
Revenue grew 17% versus the same
Sangamo Therapeutics Announces Second Quarter 2022 Conference Call and Webcast
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company has scheduled the release of its second quarter 2022 financial results after the market
Novocure Reports Second Quarter 2022 Financial Results
Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended June 30, 2022. Novocure is a global oncology company working to extend survival in some of the most aggressive forms
PFIZER REPORTS SECOND-QUARTER 2022 RESULTS
Pfizer Inc. (NYSE: PFE) reported strong financial results for second-quarter 2022 and updated certain components of 2022 financial guidance(4). Pfizer reaffirmed its previous 2022 revenue guidance
PFIZER REPORTS SECOND-QUARTER 2022 RESULTS
Pfizer Inc. (NYSE: PFE) reported strong financial results for second-quarter 2022 and updated certain components of 2022 financial guidance(4). Pfizer reaffirmed its previous 2022 revenue guidance
ICON Shareholders Vote in Favour of All Resolutions at its Annual General Meeting
ICON plc (NASDAQ: ICLR) ) (“ICON”), a world-leading healthcare intelligence and clinical research organisation, today announced that all resolutions at the Annual General Meeting of the Company
Xencor to Host Second Quarter 2022 Financial Results Webcast and Conference Call on August 3, 2022
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced it will
Acadia Healthcare Reports Second Quarter 2022 Results and Raises 2022 Guidance
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced financial results for the second quarter ended June 30, 2022.
Second Quarter Highlights
-
Revenue totaled $651.7 million, an
ICON Reports Second Quarter 2022 Results
ICON plc (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organization, today reported its financial results for the second quarter ended June 30, 2022.
CEO Dr. Steve
Agilent 2022 Early Career Professor Award Presented to Stefanos Nikolaidis
Agilent Technologies Inc. (NYSE: A) announced today that Stefanos Nikolaidis Ph.D. has received the Agilent 2022 Early Career Professor Award. Dr. Stefanos Nikolaidis is an Assistant Professor of
Novocure Announces Recipients of 4th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program
Novocure today announced the recipients of the 4th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program. The AACR-Novocure Grants for Tumor Treating Fields Research Program
DGAP-Adhoc: Eckert & Ziegler: Strong Growth in Revenues and Earnings in 2nd Quarter
DGAP-Adhoc: Eckert & Ziegler: Strong Growth in Revenues and Earnings in 2nd Quarter
Aurinia Pharmaceuticals Notification Regarding Inter Partes Patent Review
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) today received notice regarding the U.S. Patent Office (USPTO) Patent Trial and Appeal Board (PTAB) decision to institute
Simulations Plus Presented New Scientific Developments at PAGE 2022
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced the presentation of five scientific
Aurinia Pharmaceuticals to Release Second Quarter 2022 Financial and Operational Results on August 4, 2022
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) today announced that it will release financial and operational results for the second quarter of 2022 on Thursday, August 4